Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27573617 | 0.82 | FADS1 (0.60) | GRM2FADS1 | |
| SCHEMBL27573619 | 0.82 | FADS1 (0.60) | GRM2FADS1 | |
| SCHEMBL9846424 | 0.81 | GRM2 (0.50) | GRM2FADS1 | |
| SCHEMBL27468588 | 0.78 | USP30 (0.46) | GRM2FADS1 | |
| SCHEMBL27461343 | 0.78 | FADS1 (0.43) | GRM2FADS1 | |
| SCHEMBL27461345 | 0.78 | FADS1 (0.43) | GRM2FADS1 | |
| SCHEMBL6266797 | 0.77 | GRM2 (0.57) | GRM2FADS1 | |
| SCHEMBL6268966 | 0.76 | GRM2 (0.72) | GRM2 | |
| SCHEMBL28009037 | 0.74 | FADS1 (0.41) | GRM2FADS1 | |
| SCHEMBL28009036 | 0.74 | FADS1 (0.41) | GRM2FADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094900-B2 | N-Aryl-2-oxazolidinones and their derivatives | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1539745-B1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1539745-A1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | GADWOOD ROBERT C (US) | 2004-04-15 | — | — | US | disclosed |
| WO-2004014897-A1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | OXA1L, NDUFS7, NDUFS6 | GRM2 4266/4885FADS1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.